Company / Cash & Equivalents
Minerva Neurosciences, Inc. Cash & Equivalents History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$21.4M
FY2024
5-year range
$21.4M / $60.8M
FY2020-FY2024
Trend
-47.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $21M in FY2024 to $61M in FY2021.
Based on SEC 10-K filings.
$21M in FY2024 with a 5-year CAGR of -0.0%.
Declined from $36M to $21M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -29.4%
- 5-Year CAGR
- -0.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -0.0%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 47.8% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -10.64 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $21.4M | -47.8% |
| FY2023 | $40.9M | +13.4% |
| FY2022 | $36.1M | -40.6% |
| FY2021 | $60.8M | +139.6% |
| FY2020 | $25.4M | +18.4% |
| FY2019 | $21.4M | -57.4% |
| FY2018 | $50.2M | +92.8% |
| FY2017 | $26.1M | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026